In ALS, the brain's support cells may be starving motor neurons — in lab models

Most ALS research focuses on the motor neurons that die. But a new study in Nature Neuroscience points the finger at their neighbors: using stem cells derived from ALS patients, researchers showed that astrocytes — the brain's support cells — carrying the C9ORF72 mutation directly sabotage mitochondrial transport inside motor neuron axons. And when the team boosted the astrocytes' mitochondrial metabolism, the transport deficit reversed — suggesting a therapeutic strategy that fixes the support crew rather than the neurons themselves.

The experiment: patient cells, watched live

The team built their models from human induced pluripotent stem cells: three patient-derived lines carrying the C9ORF72 mutation, each paired with a CRISPR gene-corrected control, differentiated into spinal-cord-patterned astrocytes and motor neurons. Using live imaging, they measured two features of axonal mitochondrial transport — the percentage of mitochondria on the move and their average speed.

Mutant astrocytes cut both measures in healthy motor neurons. Strikingly, the reverse also held: culturing mutant motor neurons with corrected astrocytes rescued both deficits to wild-type levels. The axon's fate was decided by the astrocyte's genotype, not the neuron's. Conditioned medium alone did nothing — direct contact was required — and the deficit was specific to mitochondria; endosome transport was untouched.

Fix the support crew's power plants

The rescue experiment is the one to watch. Boosting mitochondrial metabolism in the mutant astrocytes — via PGC-1α, the master regulator of mitochondrial biogenesis — was sufficient to reverse the transport deficits in the neurons they touched. Seahorse assays and membrane-potential measurements confirmed the astrocytes were directly perturbing neuronal mitochondrial bioenergetics.

This reframes the therapeutic target: not just the dying motor neuron, but the metabolic health of the astrocytes surrounding it. It is still entirely preclinical — cell models, no animals, no patients — but it opens a non-cell-autonomous avenue in a disease where neuron-focused strategies have repeatedly fallen short.

Where the evidence stands

• Established: C9ORF72 mutation is the commonest cause of familial ALS and accounts for about 10% of sporadic cases; axonal transport of mitochondria is critical for neuronal function and survival.
• Preliminary: Patient-derived stem-cell models (three C9ORF72 lines plus CRISPR gene-corrected controls): mutant astrocytes reduced the percentage and speed of motile mitochondria in motor-neuron axons; the astrocyte's genotype — not the neuron's — determined the phenotype; boosting astrocytic mitochondrial metabolism via PGC-1α reversed the deficit. No animal or human treatment data.
• Absent: Any therapy based on this mechanism; proof that fixing astrocyte mitochondria slows ALS in living patients.